[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-sjgren-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-sjgren-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,76,100,122,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100611862","early-phase-1-exploratory-clinical-study-on-the-safety-and-efficacy-of-anti--cd19bcma-u-car-t-cell-injection-for-the-treatment-of-relapsedrefractory-autoimmune-diseases-100611862",false,"NCT07246096","Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19\u002FBCMA U CAR-T Cell Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19\u002FBCMA Universal CAR-T Cell Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","Common inclusion criteria:\n\n1. Age: ≥ 18 years old and ≤ 70 years old, male or female;\n2. The functions of critical organs meet the following requirements:\n\na )Neutrophil count ≥ 1 x 10\\^9\u002FL, Hemoglobin ≥60g\u002FL; b) Liver function: ALT ≤ 3 x ULN,AST≤3 x ULN, TBIL≤1.5 x ULN; c) Coagulation function: International standardized ratio (INR) ≤1.5x ULN, prothrombin time (PT) ≤1.5 x ULN; d) Cardiac function: good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥50%; 3. Female subjects of childbearing potential and male subjects whose partner is a female of childbearing potential are required to use medically approved contraception or abstain from sex for at least 6 months during and at least 6 months after the end of the study treatment period; female subjects of childbearing potential have had a negativeserum HCG test within 7 days prior to study enrollment and are not lactating; 4. Voluntarily participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nSpecific inclusion criteria:\n\nRelapsed\u002FRefractory Systemic lupus erythematosus\n\n1. Subject have previous diagnosis of systemic lupus erythematosus (SLE) (according to the 1997 American College of Rheumatology revised SLE classification criteria, the 2012 Systemic Lupus International Collaborating Clinics classification criteria, or the 2019 European League Against Rheumatism\u002FAmerican College of Rheumatology joint classification criteria);\n2. Subjects had a modified SLEDAI-2K score of ≥8 at screening;\n3. Subject has ≥ 1 organ system with BILAG-2004 Class A mobility score or ≥ 2 organ systems with BILAG-2004 Class B mobility score at screening;\n4. Based on the results of the central laboratory tests at screening, the subject meets one of the following: a. ANA by immunofluorescence ≥ 1:80 b. Anti-dsDNA antibodies above the normal level c. Anti-Smith antibodies above the normal level.\n\nRelapsed\u002FRefractory Systemic Sclerosis\n\n1. Meets 2013 ACR classification criteria for systemic sclerosis;\n2. If combined with interstitial pneumonia, interstitial changes suggestive of ground-glass exudates on chest HRCT and FVC or DLCO \\\u003C70% predictive value on pulmonary function tests;\n3. Ineffective conventional treatment or relapse of disease activity after remission. Definition of routine treatment: Use of glucocorticoids (above 1mg\u002FKg\u002Fd) and cyclophosphamide, as well as any of the following immunomodulatory drugs for more than 6 months: antimalarials,\n4. methotrexate, leflunomide, cyclophosphamide, azathioprine, mertiomate, tacrolimus, cyclosporine, and biologics, including rituximab, belimumab and tetracycline;\n5. Definition of progressiveness; 1) Definition of cutaneous progression: increase in mRSS \\>10%; 2) Definition of lung disease progression: 10% decrease in FVC or 5% decrease in FVC with 15% decrease in DLCO (OMERACT progression).\n\nRelapsed\u002FRefractory Primary Sjögren's Syndrome\n\n1. Meets 2002 AECG criteria or 2016 ACR\u002FEULAR classification criteria for primary dry syndrome (pSS);\n2. Definition of disease activity: investigator-assessed disease ESSDAI score of 5 or higher;\n3. Ineffective conventional treatment or relapse of disease activity after remission. Definition of routine treatment: Use of glucocorticoids (above 1mg\u002FKg\u002Fd) and cyclophosphamide, as well as any of the following immunomodulatory drugs for more than 6 months: antimalarials, methotrexate, leflunomide, cyclophosphamide, azathioprine, mertiomate, tacrolimus, cyclosporine, and biologics, including rituximab, belimumab and tetracycline.\n\nRelapsed\u002FRefractory rheumatoid arthritis\n\n1. Meets the diagnostic criteria of the 2010 ACR\u002FEULAR classification. Diagnosis of moderately or severely active rheumatoid arthritis with a previous diagnosis of rheumatoid arthritis ≥ 6 months;\n2. A swollen joint count of ≥ 6 (based on 66 joint counts) and a tender joint count of ≥ 6 (based on 68 joint counts) during the Screening Period;\n3. C-reactive protein (CRP) ≥ 10 mg\u002FL or erythrocyte sedimentation rate (ESR) ≥ 28 mm\u002Fh during the Screening Period;\n4. EULAR definition of refractory rheumatoid arthritis:\n\n1） Failure of treatment according to EULAR recommended guidelines and failure of treatment with ≥2 b\u002FtsDMARDs despite failure of treatment with csDMARDs. (i) unless treatment with bDMARDs\u002FtsDMARDs is limited due to socioeconomic factors; and (ii) if treatment with csDMARDs is contraindicated, then failure of treatment with ≥2 b\u002FtsDMARDs of different mechanisms also fulfills the condition); 2） Symptom management of RA is considered problematic by both the patient and the physician; 3） Signs suggestive of active or progressive disease if at least 1 of the following 5 items is met (Meeting all three of the below criteria can be diagnosed as rheumatoid arthritis): i. At least moderate disease activity (DAS28-ESR \\>3.2 or CDAI\\>10); ii. Signs and\u002For symptoms suggestive of active disease; iii. Inability to reduce glucocorticoids to less than 7.5 mg\u002Fdayprednisone or equivalent; iv. Rapid imaging progression (1-year increase of ≥5 points in vander Heijde modified Sharp score); v. Decreased quality of life due to RA, although RA is well controlled.\n\nRelapsed\u002Frefractory anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis\n\n1. Meets 2022 ACR\u002FEULAR diagnostic criteria for ANCA vasculitis, including microscopic polyangiitis, granulomatous polyangiitis, eosinophilic granulomatous polyangiitis;\n2. Positive ANCA related antibodies (MPO-ANCA or PR3-ANCA positive);\n3. The Birmingham Vasculitis Activity Scale (BVAS) is ≥ 15 points (a total score of 63 points), indicating the activity of the vasculitis condition;\n4. Glomerular filtration rate (eGFR, CKD-EPI formula) ≥15 ml\u002Fmin\u002F1.73 m2 during the screening period.\n\nExclusion Criteria:\n\nSubjects who meet any of the following common exclusion criteria or disease-specific exclusion criteria will not be eligible for this study.\n\nCommon exclusion Criteria:\n\n1. Subjects with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions;\n2. Existence or suspicion of uncontrollable or treatable fungal, bacterial, viral or other infections;\n3. Subjects with central nervous system disorders caused by ADs or not caused by ADs (including epilepsy, psychiatric disorders, organic encephalopathy syndromes, cerebrovascular accidents, encephalitis, central nervous system vasculitis);\n4. Subjects s with relatively serious heart diseases, such as angina pectoris, myocardial infarction, heart failure, and arrhythmia;\n5. Subjects with congenital immunoglobulin deficiency;\n6. Subjects with malignant tumors (except for non-melanoma skin cancer and in situ cervical, bladder, and breast cancers that have been disease free for more than 5 years);\n7. Subjects with end-stage renal failure;\n8. Subjects with positive hepatitis B surface antigen (HBsAg) or hepatitis,B core antibody (HBcAb) and HBV DNA titer in peripheral blood higher than the upper limit of detection; Patients with positive hepatitis C virus (HCV) antibodies and positive peripheral blood HCV RNA; People who are positive for human immunodeficiency virus (HIV) antibodies; Those who have tested positive for syphilis;\n9. Subjects with mental illness and severe cognitive impairment;\n10. Subjects who have received other clinical trial treatment within 6 months;\n11. Pregnant or intending to conceive women;\n12. Subjects with hypertension or diabetes that cannot be controlled by medication;\n13. In the opinion of the investigator, there are other reasons that prevent some subjects from being included in this study.\n\nSpecific exclusion Criteria:\n\nRelapsed\u002FRefractory Systemic lupus erythematosus\n\n1. Except for SLE, any clinically significant history of cardiac, endocrine, blood, liver, immune, metabolic, urinary, pulmonary, neurological, skin, psychiatric, or renal disorders, or other major diseases that may interfere with the administration of KN3601 (as determined by the investigator);\n2. Except for SLE, any active skin disease that could interfere with the research evaluation of SLE including but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-SLE cutaneous lupus manifestations (such as cutaneous vasculopathy, periungual capillary dilation, fingertip sclerosis, rheumatoid nodules, erythema multiforme, leg ulcers) or drug-induced lupus.\n\nRelapsed\u002FRefractory Primary Sjögren's Syndrome\n\n1\\. SSc-like disease caused by environmental, ingestion, or injection factors, accompanied by other autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, polymyositis, etc.).\n\nRelapsed\u002FRefractory dry syndrome\n\n1. Combined cirrhosis of the liver;\n2. Combination of aplastic anemia (AA), myelodysplastic syndrome (MDS), or other myeloproliferative disease (MPD).\n\nRelapsed\u002FRefractory rheumatoid arthritis\n\n1\\. Functional status of rheumatoid arthritis graded at level 4 according to ACR.\n\nRelapsed\u002Frefractory ANCA-associated vasculitis\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m2;\n2. If the patient has alveolar hemorrhage invasive lung ventilation is required, estimated to last longer than the screening period.","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19\u002FBCMA U CAR T cells in patients with autoimmune diseases.\n\n60 patients are planned to be enrolled in the dose-escalation trial.",[27,28,29,30,31,32],"Autoimmune Diseases","Systemic Lupus Erythematosus","Systemic Sclerosis","Primary Sjögren Syndrome","Rheumatoid Arthritis","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","RECRUITING","2026-02-23",{"date":36,"type":37},"2026-02-25","ACTUAL",{"date":39,"type":21},"2026-02-20",{"date":41,"type":21},"2028-07-20",{"name":43,"class":44},"Changhai Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100324827","medico-economic-and-quality-of-life-impact-of-sjogren-associated-small-fiber-neuropathy-100324827","NCT03509064","Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy","The Medico-economic Impact and Quality of Life of the Small-fiber Neuropathy Associated by Using Validated Scales (SF36, DN4, PROFAD SSI, ESPRI)","SFINESS-QoLEco","Inclusion Criteria:\n\n* Definite primary Sjögren syndrome\n* Age over 18 years\n* No biologics nor immunoglobulin therapy during the 6 months before study onset\n\nArm 1: patients with a small fiber neuropathy defined by the presence of a clinical AND one paraclinical abnormality\n\n* (i) Clinical signs of small fibers involvement: thermo-algic sensory deficit or autonomic dysfunction or neuropathic pain with DN4 ≥4;\n* AND\n* (ii) Small fibers neurophysiological abnormalities (QST, laser evoked potentials, autonomic nervous system tests (sympathetic skin response test or Sudoscan®)\n* OR\n* (iii) abnormal intraepidermal nerve fiber density (skin biopsy)\n\nArm2 (control group): patients without signs of peripheral neuropathy (small or large fiber)\n\nExclusion Criteria:\n\n* Presence of other causes of peripheral neuropathy\n\n  * Acquired: Diabetes, AL amyloidosis, Alcoholism, celiac disease, Drugs, toxic, HIV, Sarcoidosis, systemic vasculitis, Guillain-Barré syndrome.\n  * Hereditary: Transthyretin hereditary amyloidosis (TTR), hereditary sensory and autonomic neuropathy (HSAN), Fabry's disease\n* Patients with impaired thermo-algic sensitivity and \u002F or dysautonomia and \u002F or pain with DN4 ≥ 4 AND normal diagnostic tests (normal neurophysiological tests AND normal skin biopsy) are excluded.",{"count":55,"type":21},100,"OBSERVATIONAL","BACKGROUND Sjögren's syndrome is an autoimmune disease whose prevalence is estimated between 200 and 500 patients per 100,000 persons in France (120 to 500,000 patients). It affects women (90%) between 40 and 60 years of age and main manifestations are generalized sicca syndrome (ocular, oral, cutaneous) and arthralgia. In 20% of cases, Sjögren's syndrome is associated with peripheral neuropathies, and the most common form is painful small fiber neuropathy (SFN). SFNs are mainly featured by neuropathic pain including burns (90%), numbness (87.5%), tingling (72.5%), electric shocks (70%) and tingling (82.5%) and also autonomic disorders (50 to 70%).\n\nHowever, there are still important issues that deserve to be investigated by clinical and basic research. Among these issues, this study will focus on:\n\n* The impact of SFN on the quality of life of patients with Sjögren's syndrome.\n* The medico-economic impact of the SFN taking into account the repercussions on the quality of life, including professional life, usual care cost (analgesics, medical and paramedical consultations, hospitalizations or emergency).\n\nEXPECTED RESULTS\n\n* Confirmation of the major impairment in the quality of life of patients with Sjogren-associated SFN\n* Analysis of correlations to highlight or not clinical or biological factors associated with quality of life impairment.\n* Evaluation of the cost attributed to the presence of an SFN in patients with Sjögren's syndrome and the pharmaco-economic interest of conventional therapeutic management (analgesic treatment, consultation pain) compared to the cost of more aggressive immunomodulatory treatments.",[30,59,60,61],"Small Fiber Neuropathy","Quality of Life","Medico-economic Impact",[63,64,65,66],"Primary sjogren syndrome","Small fiber neuropathy","Quality of life","Medico-economic impact","2026-02-04",{"date":69,"type":37},"2026-02-05",{"date":71,"type":37},"2019-01-14",{"date":73,"type":21},"2027-01-14",{"name":75,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100621815","phase-2-a-phase-2-study-on-the-safety-and-efficacy-of-the-anti-baff-r-monoclonal-antibody-esg206-in-patients-with-primary-sjogren-syndrome-100621815","NCT07375524","A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome","Inclusion Criteria:\n\n* Adults (≥18 years of age) with a confirmed diagnosis of primary Sjögren's syndrome according to the 2016 American College of Rheumatology (ACR) \u002F European League Against Rheumatism (EULAR) classification criteria.\n* Evidence of active disease at screening\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Secondary Sjögren's syndrome or other clinically significant autoimmune or inflammatory diseases\n* Prior or recent use of prohibited immunomodulatory therapies\n* Clinically significant infections, malignancies, or uncontrolled medical conditions\n* Pregnancy or breastfeeding",{"count":83,"type":21},40,[85],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.",[30],"NOT_YET_RECRUITING","2026-01-30",{"date":91,"type":37},"2026-02-03",{"date":93,"type":21},"2026-03-01",{"date":95,"type":21},"2028-06-30",{"name":97,"class":98},"Shanghai Escugen Biotechnology Co., Ltd","INDUSTRY",21,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":45},"100617908","exploring-the-novel-value-of-psma-pet-in-sjgrens-syndrome-integrated-analysis-with-established-fapi-pet-imaging-100617908","NCT07324733","Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging","Inclusion Criteria:\n\n* Age 18-80 years;\n* Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment. OR diagnosis of a solid tumor scheduled for FAPI PET imaging\n\nExclusion Criteria:\n\n* Combined with tumors or other connective tissue diseases (for SS group);\n* Patients who are currently using hormones\u002Fbiological agents (for both groups)；\n* Pregnancy or lactation","80 Years",{"count":20,"type":21},[109],"NA","Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis. Conventional imaging provides limited ability to simultaneously evaluate glandular function and inflammatory activity, leading to challenges in disease staging and treatment decision-making. This study explores a conceptual dual-tracer imaging framework using PSMA PET and FAPI PET to delineate complementary biological processes in pSS.",[30,112],"PET","2025-12-24",{"date":115,"type":37},"2026-01-07",{"date":117,"type":37},"2025-09-01",{"date":119,"type":21},"2026-05-30",{"name":121,"class":44},"Peking Union Medical College Hospital",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":129,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100549935","phase-2-a-study-of-rslv-132-in-females-with-sjgrens-disease-100549935","NCT06440525","A Study of RSLV-132 in Females With Sjögren's Disease","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sjögren's Disease With Moderate to Severe Symptom Burden","Inclusion Criteria:\n\n* Providing written informed consent\n* Weight at least 45 kg\n* Meet the 2016 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) Classification Criteria for pSS\n* Diagnosis in the last 30 years\n* Positive anti-Ro\u002FSSA antibody test\n* Score of 5 or higher on the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) scale and the ESSPRI fatigue scale\n* Of non childbearing potential or of childbearing potential and using highly effective contraceptive measures\n\nExclusion Criteria:\n\n* Diagnosis of any active autoimmune disease other than pSS that could affect the efficacy assessments\n* Uncontrolled hypothyroidism or severe fibromyalgia\n* New medications or change in medications in the last 4 weeks for pSS symptoms\n* Receipt of other prohibited medications\n* Apheresis or blood donation\n* Allergic reaction to RSLV-132 or biologic therapy\n* Clinically significant infection in last 30 days\n* Participation in another clinical study\n* Malignancy in last 5 years\n* Positive test for HIV or hepatitis\n* Major surgery in last 30 days or anticipated surgery during the study\n* Pregnancy or breast feeding\n* Laboratory blood tests outside of specified ranges\n* Other medical conditions or medications that would make the participant unsuitable","FEMALE","75 Years",{"count":132,"type":21},106,[85],"The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are:\n\n* Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain?\n* Does RSLV-132 improve the tiredness\u002Ffatigue caused by Sjogren's?\n* What are the blood levels of RSLV-132 over time?\n* What is the immune (antibody) response in the body to RSLV-132?\n* What is the safety profile of RSLV-132?\n\nResearchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS.\n\nParticipants will:\n\nTake RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device",[30],"2025-07-15",{"date":138,"type":37},"2025-07-18",{"date":140,"type":37},"2024-12-01",{"date":142,"type":21},"2027-03-01",{"name":144,"class":98},"Resolve Therapeutics",24,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":153,"targetDuration":155,"studyType":56,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100556676","construction-of-clinical-model-of-primary-sjogrens-syndrome-combined-traditional-chinese-and-western-medicine-100556676","NCT06528197","Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western Medicine","Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese Medicine and Western Medicine Based on Multi-omics","Inclusion Criteria:\n\n* Meets the 2002 AECG or 2016 ACR\u002FEULAR classification criteria of primary Sjögren's syndrome.\n\nExclusion Criteria:\n\n* Comorbid connective tissue disease other than the disease under research.\n* Women who are pregnant or breastfeeding.\n* Combined severe cardiovascular or cerebrovascular disease, hepatic or renal failure, or severe malignant tumors.\n* Other conditions (e.g., cognitive impairment) that the investigators consider ineligible for enrollment.",{"count":154,"type":21},1000,"30 Months","This study aims to establish a large sample cohort of patients with primary sjogren's syndrome, collect multi-omics information of patients with primary sjogren's syndrome, and construct disease diagnosis model and disease prognosis prediction model.",[30],"2024-07-29",{"date":160,"type":37},"2024-07-30",{"date":162,"type":37},"2024-07-04",{"date":164,"type":21},"2026-12-31",{"name":166,"class":44},"China-Japan Friendship Hospital"]